Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kissei Pharmaceutical CoTSE:4547 +0.13%79 Net Margin % is 11.16% as of Mar. 2026, which is 13% below its 10-year median of 12.88. GuruFocus rates TSE:4547 with a GF Score™ of 79/100 and a GF Value™ of 円4,688.48 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 962 Drug Manufacturers companies, Kissei Pharmaceutical Co ranks better than 76.4% on this metric.
Kissei Pharmaceutical Co (TSE:4547) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kissei Pharmaceutical Co Net Margin % Related Terms
Kissei Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kissei Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kissei Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kissei Pharmaceutical Co (TSE:4547) has a Net Margin % of 11.16% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kissei Pharmaceutical Co and its competitors. This is 13% below median its historical median of 12.88. Over the past decade, Kissei Pharmaceutical Co's Net Margin % has ranged from 4.45 to 19.76. According to the industry distribution chart, Kissei Pharmaceutical Co ranks #227 out of 962 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Kissei Pharmaceutical Co's Net Margin % too high?
Kissei Pharmaceutical Co's current Net Margin % of 11.16% is 13% below median its 10-year median of 12.88. Over the past 10 years, this metric has ranged from a low of 4.45 to a high of 19.76. The Drug Manufacturers industry median Net Margin % is 5.37. Kissei Pharmaceutical Co's value of 11.16% is 107.8% above this industry median. Based on the distribution chart, Kissei Pharmaceutical Co ranks #227 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kissei Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kissei Pharmaceutical Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kissei Pharmaceutical Co ranks #227 out of 962 companies for Net Margin %. This places Kissei Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.37. Kissei Pharmaceutical Co's value of 11.16% is 107.8% above this benchmark. Historically, Kissei Pharmaceutical Co's own Net Margin % has ranged from 4.45 to 19.76 over the past decade. While the company's 10-year median is 12.88 vs. the industry median of 5.37, Kissei Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.37, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kissei Pharmaceutical Co's current Net Margin % of 11.16% is 107.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kissei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kissei Pharmaceutical Co's current Net Margin % is 11.16%, which is 13% below median its own 10-year median of 12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kissei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co (TSE:4547) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,688.48, compared to a current price of 円3,860.00 — trading 17.7% below its estimated fair value. The current Net Margin % is 11.16%, which is 13% below median its 10-year median of 12.88 and 107.8% above the Drug Manufacturers industry median of 5.37. Kissei Pharmaceutical Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kissei Pharmaceutical Co (TSE:4547), the current Net Margin % is 11.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kissei Pharmaceutical Co (TSE:4547) Overvalued in 2026?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円3,860.00 is trading 17.7% below its estimated GF Value™ of 円4,688.48.
GuruFocus considers Kissei Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4547:
Net Margin %: 11.16% (13% below median its 10-year median of 12.88)
GF Value™: 円4,688.48 vs. price of 円3,860.00 (17.7% below fair value)
Industry Position: 107.8% above the Drug Manufacturers median (#227 of 962)
No single metric tells the full story. See the TSE:4547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
79GF Score
Get the complete analysis for TSE:4547
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4547 has been successfully added to your 
